ENSC התחייבויות חוב מצטברות Ensysce Biosciences Inc.

Ensysce Biosciences (ENSC) develops abuse-deterrent analgesics through partnerships with medical centers, which increases the likelihood of an acquisition. The company's price chart on GURU.Markets based on the separate_debt metric is 0.00. A stable raw material reserve and flexible supply routes ensure operational continuity. Proprietary formulas provide high growth potential, enabling low-cost drug production for the global market following certification.

The development of Ensysce Biosciences (ENSC) proprietary TAAP and MPAR platforms requires significant R&D investment to maintain a technological edge in the opioid protection sector. GURU.Markets analytics tracks operational changes in total borrowed capital via the debt load trajectory, allowing investors to assess the balance between the cost of capital and the risk of liquidity loss amid a volatile borrowing market.